Key factors in the acceptability of treatment as prevention (TasP) in Scotland: a qualitative study with communities affected by HIV - PubMed (original) (raw)

Key factors in the acceptability of treatment as prevention (TasP) in Scotland: a qualitative study with communities affected by HIV

I Young et al. Sex Transm Infect. 2015 Jun.

Abstract

Objectives: There is a clear need to understand the factors that might prevent and/or facilitate the effective use of HIV treatment as prevention (TasP) at an individual level. This paper reports on findings from the first qualitative study in the UK exploring the acceptability of TasP among gay, bisexual and/or men who have sex with men (MSM) and migrant African communities in Scotland.

Methods: We conducted seven exploratory focus group discussions (FGDs) with convenience samples of MSM (five FGDs, n=22) and mixed-gender African (two FGDs, n=11) participants. Of these, three FGDs were conducted with HIV-positive MSM (n=14) and one FGD with HIV-positive Africans (n=8). We then conducted 34 in-depth interviews (IDIs) with a purposive sample of MSM (n=20) and Africans (n=14, women=10). Half were HIV-positive (MSM, n=10; African, n=7). FGD and IDI data were analysed thematically drawing on predetermined and emergent themes.

Results: We found that inequalities in HIV literacy could be a barrier to TasP, as could social constraints, such as criminalisation of transmission, increased risk of sexually transmitted infection and increased burden of treatment. We also identified psychological barriers such as perceptions of risk. However, relationships and shared decision making were identified as potential facilitators for TasP.

Conclusions: Our results suggest that potential use and management of TasP may not be straightforward. It could be contingent on reducing inequalities in HIV literacy, minimising the perceived burden of treatment and other potential risks, and addressing the dynamics of existing and socially acceptable risk management strategies, especially in relation to long-term serodiscordant relationships.

Keywords: GAY MEN; HIV; PROPHYLAXIS; PUBLIC HEALTH; QUALITATIVE RESEARCH.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.

PubMed Disclaimer

Figures

Figure 1

Treatment as prevention (TasP) card.

References

1. Cohen MS, McCauley M, Gamble TR. HIV treatment as prevention and HPTN 052. Curr Opin HIV AIDS 2012;7:99–105. -PMC -PubMed
1. Vernazza PL. The debate continues: does ‘undetectable’ mean ‘uninfectious’? HIV therapy 2009;3:113–16.
1. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010;376:532–9. -PMC -PubMed
1. BHIVA, EAGA. Position statement on the use of antiretroviral therapy to reduce HIV transmission January 2013, British HIV Association (BHIVA) and the Expert Advisory Group on AIDS (EAGA). HIV Med 2013;14:259–62. -PubMed
1. Das M, Chu PL, Santos GM, et al. Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS ONE 2010;5:e11068. -PMC -PubMed

Key factors in the acceptability of treatment as prevention (TasP) in Scotland: a qualitative study with communities affected by HIV - PubMed (original) (raw)